Breaking news

The objective of this randomized clinical trial was to determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14.

This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States.

In this article the authors report cryo-EM structures of the full-length spike (S) trimers of the B.1.1.7 and B.1.351 variants, as well as their biochemical and antigenic properties.

In this article the authors combine cryo-EM, binding and computational analyses to study variant spikes, including one that was involved in transmission between minks and humans, and others that originated and spread in human populations.

A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).

In this article the authors identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants.

In this article the authors isolated an infectious Delta strain from a traveller returning from India.

In this double-blind, randomised, placebo-controlled phase 3 trial the authors present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.

In this article the authors assessed whether azithromycin is effective in reducing hospital admission in patients with mild-to-moderate COVID-19.

In this systematic review and meta-analysis, the authors searched various databases between Jan 1, 2020, and March 5, 2021, for original studies reporting data on COVID-19 outcomes in patients with psychiatric disorders compared with controls.

In this article the authors conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups.

In this article the authors conducted a single-center, open-label, non-randomized, Phase 1 trial in India between July 2020 and October 2020.

This phase 3 trial randomly assigned a cohort of patients with mild or moderate COVID-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent or placebo within 3 days after a laboratory diagnosis of SARS-CoV-2 infection.

In this article the authors assess 88 health care workers who had received one dose of ChAdOx1 nCoV-19 vaccine 9 to 12 weeks earlier. Among these participants, 37 chose a homologous boost with ChAdOx1 nCoV-19 and 51 chose a heterologous boost with mRNA-1273 (Moderna).

In this article the authors used a test-negative case–control design to estimate the effectiveness of vaccination against symptomatic disease caused by the delta variant or the predominant strain (B.1.1.7, or alpha variant) over the period that the delta variant began circulating.